SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.

Article Details

Citation
Copy to clipboard

Poland GA, Ovsyannikova IG, Kennedy RB

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates.

Lancet. 2020 Nov 14;396(10262):1595-1606. doi: 10.1016/S0140-6736(20)32137-1. Epub 2020 Oct 13.

PubMed ID
33065034 [ View in PubMed
]
Abstract

Understanding immune responses to severe acute respiratory syndrome coronavirus 2 is crucial to understanding disease pathogenesis and the usefulness of bridge therapies, such as hyperimmune globulin and convalescent human plasma, and to developing vaccines, antivirals, and monoclonal antibodies. A mere 11 months ago, the canvas we call COVID-19 was blank. Scientists around the world have worked collaboratively to fill in this blank canvas. In this Review, we discuss what is currently known about human humoral and cellular immune responses to severe acute respiratory syndrome coronavirus 2 and relate this knowledge to the COVID-19 vaccines currently in phase 3 clinical trials.

DrugBank Data that Cites this Article

Drugs